A randomized, prospective trial of ribavirin 400 mg/Day versus 800 mg/Day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3

被引：58

作者：

Ferenci, Peter ^{[1
]}

Brunner, Harald ^{[2
]}

Laferl, Hermann ^{[3
]}

Scherzer, Thomas-Matthias ^{[1
]}

Maieron, Andreas ^{[4
]}

Strasser, Michael ^{[5
]}

Fischer, Gabriele ^{[6
]}

Hofer, Harald ^{[1
]}

Bischof, Martin ^{[7
]}

Stauber, Rudolf ^{[8
]}

Gschwantler, Michael ^{[9
]}

Steindl-Munda, Petra ^{[1
]}

Staufer, Katharina ^{[1
]}

Loeschenberger, Karin ^{[10
]}

机构：

[1] Med Univ, Dept Internal Med 3, Vienna, Austria

[2] Hosp Hietzing, Dept Internal Med 1, Vienna, Austria

[3] Kaiser Franz Josef Spital, Dept Internal Med, Vienna, Austria

[4] Elisabethinen Hosp, Dept Internal Med, Linz, Austria

[5] St Josef Hosp, Dept Internal Med 1, Salzburg, Austria

[6] Med Univ, Dept Psychiat, Vienna, Austria

[7] Rudolfsspital, Dept Internal Med 4, Vienna, Austria

[8] Med Univ, Dept Internal Med, Graz, Austria

[9] Wihelminenspital, Dept Internal Med 4, Vienna, Austria

[10] Roche Austria, Vienna, Austria

来源：

HEPATOLOGY | 2008年 / 47卷 / 06期

关键词：

D O I：

10.1002/hep.22262

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

We compared the efficacy and tolerability of 24 weeks of treatment with ribavirin 800 mg/day (group A) or 400 mg/day (group B) plus peginterferon alfa-2a 180 mu g/week in treatment-naive patients infected with hepatitis C virus (HCV) genotype 2 or 3. A total of 97 of 141 patients randomized to group A (68.8%, 95% confidence interval [CI] 60.5%-76.3%) and 90 of 141 patients randomized to group B (63.8; 95% CI 55.3%-71.7%) achieved a sustained virological response, defined as undetectable serum HCV RNA at the end of untreated follow-up (week 48). Among patients infected with genotype 3, the rate of sustained virological response was 67.5% (95% CI 58.4%-75.6%) in group A and 63.9% (95% CI 54.7%-72.4%) in group B, and among patients infected with genotype 2, the rate of sustained virological response was 77.8% (95% CI 54.2%-93.6%) in group A and 55.6% (95% CI 38.4%-83.7%) in group B. Relapse rates in the 2 treatment groups were similar (17% in group A and 20% in group B). The incidence of adverse events, laboratory abnormalities, and dose reductions was similar in the 2 treatment groups. Conclusion: The results suggest that when administered for 24 weeks with peginterferon alfa-2a, ribavirin doses of 400 and 800 mg/day produce equivalent outcomes in patients infected with HCV genotype 3.

引用

页码：1816 / 1823

页数：8

共 20 条

[1]

ALTER H, 2007, J HEPATOL, V43, P550

[2] RNA virus error catastrophe: Direct molecular test by using ribavirin [J].